Current Management of Patients with HCV Genotype 1
- 11 May 2021
- book chapter
- other
- Published by Springer Science and Business Media LLC
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported OutcomesClinical Infectious Diseases, 2017
- Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertensionJournal of Viral Hepatitis, 2017
- From HCV To HBV CureLiver International, 2017
- Direct‐acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN‐free treatment and future perspectivesLiver International, 2016
- Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 InfectionThe New England Journal of Medicine, 2015
- Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 InfectionThe New England Journal of Medicine, 2015
- Sofosbuvir for the treatment of hepatitis C virusExpert Opinion on Pharmacotherapy, 2013
- 1191 GS-5816, A SECOND GENERATION HCV NS5A INHIBITOR WITH POTENT ANTIVIRAL ACTIVITY, BROAD GENOTYPIC COVERAGE AND A HIGH RESISTANCE BARRIERJournal of Hepatology, 2013
- Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirinHepatology, 2009
- Eradication of Hepatitis C Virus in Patients Successfully Treated for Chronic Hepatitis CGastroenterology, 2008